Agios Reports Strong Q4/FY25 Results, Highlights Successful AQVESME Launch & Sickle Cell Progress
Summary
Agios Pharmaceuticals reported strong fourth quarter and full year 2025 financial results, driven by significant revenue growth for PYRUKYND and the successful U.S. launch of AQVESME for thalassemia, alongside positive progress in its sickle cell disease program.
Key Events
-
Strong Q4 and Full Year 2025 Financial Results
Agios reported Q4 2025 net loss of $108.0 million and full year 2025 net loss of $412.8 million. PYRUKYND U.S. net revenue grew 49% year-over-year to $16.0 million in Q4 2025, with total product revenue for FY 2025 reaching $54.0 million.
-
Successful U.S. Launch of AQVESME™
Following FDA approval in December 2025, AQVESME™ (mitapivat) for thalassemia is now available in the U.S. and has received an enthusiastic response from the thalassemia community, marking a key commercial milestone.
-
Advancing Mitapivat in Sickle Cell Disease
Agios plans a pre-sNDA meeting with the FDA in Q1 2026 for mitapivat in sickle cell disease, with intentions to submit a U.S. marketing application following this engagement, indicating significant regulatory progress.
-
Robust Cash Position
The company ended 2025 with $1.2 billion in cash, cash equivalents, and marketable securities, providing financial independence to support ongoing commercial launches and advance its clinical pipeline.
Analysis
Agios Pharmaceuticals delivered solid financial results for Q4 and full year 2025, marked by robust revenue growth for PYRUKYND and the successful U.S. commercial launch of AQVESME for thalassemia. The company's strong cash position provides a substantial runway for continued product launches and pipeline advancement, including the upcoming pre-sNDA meeting for mitapivat in sickle cell disease. These operational and financial achievements underscore the company's execution in expanding its rare disease franchise.
At the time of this filing, AGIO was trading at $28.55 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.6B. The 52-week trading range was $22.24 to $46.00. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.